Phase II trial of volasertib (BI 6727) versus chemotherapy (CT) in platinum-resistant/refractory ovarian cancer (OC)

被引：0

作者：

Pujade-Lauraine, Eric

Weber, Beatrice E.

Ray-Coquard, Isabelle

Vergote, Ignace

Selle, Frederic

Del Campo, Jose Maria

Sufliarsky, Jozef

Tschoepe, Inga

Chesa, Pilar Garin

Nazabadioko, Serge

Pilz, Korinna

Joly, Florence

机构：

[1] Hop Hotel Dieu, AP HP, Unite Oncol Med, F-75181 Paris, France

[2] Ctr Alexis Vautrin, Vandoeuvre Les Nancy, France

[3] Ctr Leon Berard, F-69373 Lyon, France

[4] Katholieke Univ Leuven, Univ Hosp Leuven, Leuven Canc Inst, Leuven, Belgium

[5] Katholieke Univ Leuven, Univ Hosp Leuven, Leuven, Belgium

[6] Hop Tenon, F-75970 Paris, France

[7] Vall dHebron Inst Oncol, Barcelona, Spain

[8] Natl Canc Inst, Bratislava, Slovakia

[9] Boehringer Ingelheim GmbH & Co KG, Reims, France

[10] Boehringer Ingelheim GmbH & Co KG, Vienna, Austria

[11] Boehringer Ingelheim GmbH & Co KG, Biberach, Germany

[12] Ctr Francois Baclesse, F-14021 Caen, France

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

5504

引用

页数：1